Results 21 to 30 of about 7,778 (203)

Pan-cancer analysis reveals that G6PD is a prognostic biomarker and therapeutic target for a variety of cancers

Frontiers in Oncology, 2023
BackgroundDespite accumulating evidence revealing that Glucose-6-phosphate dehydrogenase (G6PD) is highly expressed in many tumor tissues and plays a remarkable role in cancer tumorigenesis and progression, there is still a lack of G6PD pan-cancer ...
Tao Zeng, Tao Zeng, Bin Li, Xin Shu, Jiahui Pang, Heping Wang, Xianghao Cai, Yingying Liao, Xiaolong Xiao, Yutian Chong, Jiao Gong, Xinhua Li   +11 more
exaly   +3 more sources

Risks of Hemolysis in Glucose-6-Phosphate Dehydrogenase Deficient Infants Exposed to Chlorproguanil-Dapsone, Mefloquine and Sulfadoxine-Pyrimethamine as Part of Intermittent Presumptive Treatment of Malaria in Infants. [PDF]

PLoS ONE, 2015
Chlorproguanil-dapsone (CD) has been linked to hemolysis in symptomatic glucose-6-phosphate dehydrogenase deficient (G6PDd) children. Few studies have explored the effects of G6PD status on hemolysis in children treated with Intermittent Preventive ...
Eugenie Poirot, Eric Vittinghoff, Deus Ishengoma, Michael Alifrangis, Ilona Carneiro, Ramadhan Hashim, Vito Baraka, Jacklin Mosha, Samwel Gesase, Daniel Chandramohan, Roland Gosling   +10 more
doaj   +6 more sources

Molecular genotyping of G6PD mutations for neonates in Ningbo area [PDF]

Journal of Clinical Laboratory Analysis, 2021
AbstractThe aim of this study is to determine the cut‐off value of glucose‐6‐phosphate dehydrogenase (G6PD) activity and the mutation spectrum of G6PD gene in neonates with G6PD deficiency at Ningbo. Around 82233 neonatal blood samples were measured to determine G6PD activity. The positive samples were further detected with gene analysis.
Jiewen Pan, Danyan Zhuang, Qi Yu, Xiaoli Pan, Youwei Bao, Shuqing Pan, Fei Wang, Lisha Ge, Haibo Li   +8 more
openaire   +2 more sources

Concordance between glucose-6-phosphate dehydrogenase (G6PD) genotype and phenotype and rasburicase use in patients with hematologic malignancies. [PDF]

Pharmacogenomics J, 2019
Phenotypic rather than genotypic tests remain the gold standard for diagnosing glucose-6-phosphate dehydrogenase (G6PD) deficiency. However, with increasing use of genomic arrays and whole exome or genome sequencing, G6PD genetic data are increasingly available.
Robinson KM, Yang W, Haidar CE, Hankins JS, Jay DW, Kornegay N, Rubnitz JE, Broeckel U, Cheng C, Pui CH, Jeha S, Relling MV.   +11 more
europepmc   +4 more sources

Lower efficacy of transfusion of red blood cells from donors with sickle cell trait. [PDF]

Hemasphere
Abstract Sickle cell trait (SCT), the heterozygous state for the hemoglobin S (HbS) mutation, affects roughly 1 in 13 African American individuals and is common among blood donors recruited for antigen‐matched transfusions in sickle cell disease (SCD).
Dzieciatkowska M, Stephenson D, Hay A, Wang X, Keele GR, Nemkov T, Deng X, Stone M, Hansen KC, Kleinman S, Norris PJ, Busch MP, Page GP, Spitalnik SL, Roubinian N, Zimring JC, Thein SL, D'Alessandro A.   +17 more
europepmc   +2 more sources

Impact of the method of G6PD deficiency assessment on genetic association studies of malaria susceptibility. [PDF]

PLoS ONE, 2009
BACKGROUND:Clinical association studies have yielded varied results regarding the impact of glucose-6-phosphate dehydrogenase (G6PD) deficiency upon susceptibility to malaria.
Marla K Johnson, Tamara D Clark, Denise Njama-Meya, Philip J Rosenthal, Sunil Parikh   +4 more
doaj   +1 more source

Study of Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency and Genotype Polymorphism of G6PD B and G6PD (A+/A-) in Patients Treated for Plasmodium vivax Malaria in a Tertiary Care Hospital in North East India [PDF]

Cureus, 2020
Introduction Glucose-6-phosphate dehydrogenase (G6PD) enzyme deficiency is the most common enzymopathy in humans, and its distribution has been historically described to be closely associated with that of malaria. North East India provides optimal conditions for transmission of malaria and bears a considerable burden of Plasmodium vivax (P.
Rajkhowa, Purnima, Nath, Chandan, Dutta, Anirban, Misurya, Ishita, Sharma, Nalini, Barman, Bhupen, Longkumer, Chubalemia, Lynrah, K G, Sarmah, Devajit, Ruram, Alice   +9 more
openaire   +2 more sources

Assessment of CareStart G6PD rapid diagnostic test and CareStart G6PD biosensor in Mauritania

Infectious Diseases of Poverty, 2021
Background The elimination of Plasmodium vivax malaria requires 8-aminoquinolines, which are contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency due to the risk of acute haemolytic anaemia.
Oum Kelthoum Mamadou Djigo, Yacoub Ould Khalef, Mohamed Salem Ould Ahmedou Salem, Nicolas Gomez, Leonardo Basco, Sébastien Briolant, Ali Ould Mohamed Salem Boukhary   +6 more
doaj   +1 more source

Associations between red cell polymorphisms and Plasmodium falciparum infection in the middle belt of Ghana. [PDF]

PLoS ONE, 2014
BACKGROUND: Red blood cell (RBC) polymorphisms are common in malaria endemic regions and are known to protect against severe forms of the disease. Therefore, it is important to screen for these polymorphisms in drugs or vaccines efficacy trials.
Nicholas Amoako, Kwaku Poku Asante, George Adjei, Gordon A Awandare, Langbong Bimi, Seth Owusu-Agyei   +5 more
doaj   +1 more source

Molecular Characterization and Genotype-Phenotype Correlation of G6PD Mutations in Five Ethnicities of Northern Vietnam

Anemia, 2022
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common enzyme disorder and is caused by G6PD gene mutations. To date, more than 400 variants in the G6PD gene have been discovered, and about 160 identified variants are associated with a significant decrease in the G6PD enzyme activity.
Thi Thao Ngo, Thinh Huy Tran, Thanh Dat Ta, Thi Phuong Le, Phuoc Dung Nguyen, Mai Anh Tran, The‐Hung Bui, Thanh Van Ta, Van Khanh Tran   +8 more
openaire   +3 more sources